Vote on your pick for the top stem cell outside the box thinker and positive impactor in 2016 from the 20 choices below. The top 10 vote getters will be finalists from which I will have the tough task of picking the one winner as Stem Cell Person of the Year along with the $2,000 prize and recognition. You can vote once per day. The voting closes in 10 days on December 15th at 11:59pm Pacific Time. Read more about the 20 nominees here.
I received a score of great nominations for the Stem Cell Person of the Year 2016 Award and have briefly described the twenty nominees below. The point of the award is to honor the top positive stem cell leader who specifically thinks outside the box and takes risks. I’ve started an on-line vote where you can vote once per day for your favorite nominee(s) for Stem Cell Person of the Year. The top half or so of nominees getting the most votes will be the finalists from which I will choose …Read More
A committee of the International Society for Stem Cell Research (ISSCR) did one heck of a document dump yesterday on stem cell policy, releasing a whole bunch of policy recommendations on stem cells and more. The torrent from ISSCR included a 37-page policy statement itself as well as several papers in top journals including the Lancet, Science, and Nature. This output was the product of the members of a special ISSCR Task Force, whose members I have listed at the bottom of this post. Who …Read More
Advances in therapeutic cloning reported in the past year have been very exciting as somatic cell nuclear transfer (SCNT) can be used to produce very powerful human embryonic stem cells (ESC). These new cells are called NT-ESCs for short. Neither embryos nor reprogramming factors are needed to produce human NT-ESCs. See here, here and here for discussions of the pioneering papers reporting creation of NT-ESC including the first paper by the lab of Shoukhrat Mitalipov of OHSU, which I called the stem cell event of the year for 2013. Now that human NT-ESC …Read More
Update in 2020: It seems now after all these years that the consensus in the now more mature field is that IPSCs and ESCs are nearly identical in most cases, and both have some of the same translational challenges such as teratoma-forming activity. It’s interesting to read this post from nearly 10 years ago and the concerns that were so intense back then. An important question in the young iPS cell field has been– just how similar these reprogrammed iPS cells are to embryonic …Read More